Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy)

Moccia, Marcello; Loperto, Ilaria; Lanzillo, Roberta; Capacchione, Antonio; Carotenuto, Antonio; Triassi, Maria; Morra, Vincenzo Brescia; Palladino, Raffaele

doi:10.1186/s12913-020-05664-x

Cited by 13 publications

(22 citation statements)

References 44 publications

(72 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Adherence of about 93% is in agreement with previously reported adherence rates to subcutaneous interferon beta therapy >90% ( 23 – 25 ) with a higher adherence of Peg IFN beta-1a compared with other subcutaneous interferons ( 26 ). However, the relatively small sample size and the short follow-up are likely to affect the comparison with data from other IFN-beta studies with longer duration and more participants.…”

Section: Discussionsupporting

confidence: 91%

Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing–Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study)

et al. 2021

View full text Add to dashboard Cite

Subcutaneous (SC) interferons beta (IFN-beta) are effective therapies for the treatment of relapsing–remitting multiple sclerosis (RRMS). Factors such as dosing schedule, needle intolerance/fatigue, and side effects may impact patient satisfaction with treatment. Improvement of patient satisfaction may increase the adherence to treatment and the patient quality of life. This study was aimed at evaluating the impact of switching to “Peginterferon beta-1a (Peg-IFN beta-1a)” in patients with RRMS unsatisfied with other SC interferons. The multicenter, open-label, phase IV PLATINUM study was conducted in 32 Italian centers. The primary endpoint was changes from baseline in the score of a convenience satisfaction domain of the TSQM-9 questionnaire at 12 weeks. The secondary endpoints were patients' global satisfaction, short-term adherence to treatment, satisfaction with the injection system, effect on fatigue, disease activity, and patient inability score. A total of 193 patients were enrolled and 166 (86%) completed the study, receiving Peg-IFN beta-1a for 24 weeks. Patients switching to Peg-IFN beta-1a from other SC interferons reported a significant improvement (p < 0.001) of Convenience Score and all other scores of the TSQM-9 questionnaire at 12 and 24 weeks (p < 0.001). Peg IFN beta-1a attained very high adherence to the treatment (92 and 86% at 12 and 24 weeks, respectively) with a stable annualized relapse rate (ARR). At 24 weeks, 94% of the participants were relapse free. Adverse events (AEs), recorded on 82 patients (42%), were mild or moderate. The most common AE was flu-like syndrome (29.2%). Patients switching from SC IFN beta therapy to Peg IFN beta-1a showed high treatment satisfaction with a positive safety profile, comparable with that of other currently approved first-line injectable SC interferons. This study suggests that Peg IFN beta-1a might represent a treatment choice to improve adherence in RRMS patients unsatisfied with other SC interferons.

show abstract

Section: Discussionsupporting

confidence: 91%

Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing–Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study)

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Incremental costs were primarily driven by pharmacy costs in patients in the NR and MMR cohorts, whereas medical costs were the key drivers in patients in the SR cohort. These observations are in line with previous long-term observational studies that speculated the costs of DMTs to be important predictors of the increased cost burden [ 10 , 11 ]. We observed that patients with severe relapses incur a high cost burden, which underscores the need to prevent progression.…”

Section: Discussionsupporting

confidence: 91%

“…The disease-modifying therapies (DMTs) were invented to reduce the relapse rates, delay disease progression, and reduce future disability in patients with RRMS [ 5 , 9 ]. However, switching among the first-line DMTs is common and is an important predictor of economic burden in patients with MS [ 10 , 11 ]. Moreover, the use of high-efficacy (and costly) DMTs could prevent relapses and delay disease progression leading to savings in overall costs [ 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

Annual Cost Burden by Level of Relapse Severity in Patients with Multiple Sclerosis

2020

View full text Add to dashboard Cite

show abstract

“…Non-adherence to DMTs is common, and is associated with higher risk of relapses and disability progression [ 81 , 82 , 83 ]. However, interventions to foster adherence in MS are costly, time-consuming, and difficult to evaluate in clinical practice [ 84 , 85 ]. Different studies have applied digital technology to auto-injectors [ 59 , 65 ], needle disposal systems [ 63 ], pill bottles [ 70 ], and diaries for monitoring DMT usage, adherence, and side effects [ 60 , 64 ].…”

Section: Discussionmentioning

confidence: 99%

Digital Technology in Clinical Trials for Multiple Sclerosis: Systematic Review

Angelis

Lavorgna

Carotenuto

et al. 2021

JCM

Self Cite

View full text Add to dashboard Cite

Clinical trials in multiple sclerosis (MS) have been including digital technology tools to overcome limitations in treatment delivery and disease monitoring. In March 2020, we conducted a systematic search on pubmed.gov and clinicaltrials.gov databases (with no restrictions) to identify all relevant published and unpublished clinical trials, in English language, including MS patients, in which digital technology was applied. We used “multiple sclerosis” and “clinical trial” as the main search words, and “app”, “digital”, “electronic”, “internet” and “mobile” as additional search words, separately. Digital technology is part of clinical trial interventions to deliver psychotherapy and motor rehabilitation, with exergames, e-training, and robot-assisted exercises. Digital technology has been used to standardise previously existing outcome measures, with automatic acquisitions, reduced inconsistencies, and improved detection of symptoms (e.g., electronic recording of motor performance). Other clinical trials have been using digital technology for monitoring symptoms that would be otherwise difficult to detect (e.g., fatigue, balance), for measuring treatment adherence and side effects, and for self-assessment purposes. Collection of outcome measures is progressively shifting from paper-based on site, to internet-based on site, and, in the future, to internet-based at home, with the detection of clinical and treatment features that would have remained otherwise invisible. Similarly, remote interventions provide new possibilities of motor and cognitive rehabilitation.

show abstract

Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy)

Cited by 13 publications

References 44 publications

Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing–Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study)

Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing–Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study)

Annual Cost Burden by Level of Relapse Severity in Patients with Multiple Sclerosis

Digital Technology in Clinical Trials for Multiple Sclerosis: Systematic Review

Contact Info

Product

Resources

About